Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023198 | 1.00 | PRCP (0.55) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL7699653 | 0.82 | PRCP (0.48) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL7699747 | 0.80 | PRCP (0.46) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL7697968 | 0.78 | PRCP (0.47) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL7702576 | 0.77 | PRCP (0.43) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL7704233 | 0.75 | PRCP (0.41) | PRCPGAARECQLGID4SMN1; SMN2 | |
| SCHEMBL7704232 | 0.75 | PRCP (0.41) | PRCPGAARECQLGID4SMN1; SMN2 | |
| SCHEMBL8510021 | 0.75 | PRCP (0.33) | PRCP | |
| SCHEMBL8508972 | 0.75 | PRCP (0.53) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL7699909 | 0.71 | PRCP (0.66) | PRCPGAARECQLGID4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592684-B1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7375099-B2 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1592684-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-20040220222-A1 | Malonamide derivatives | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-11-04 | — | — | US | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| EP-0901488-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| EP-0901488-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
| US-5866583-A | Substituted 2,4-diaminopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1997043277-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220222-A1 | Malonamide derivatives | BACE1, BACE2, APP | PRCP 461/4885GAA 114/4885RECQL 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.